BRIEF-Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib

Reuters
25 Jun
BRIEF-Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib

June 25 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O:

  • CORVUS PHARMACEUTICALS ANNOUNCES PARTNER ANGEL PHARMACEUTICALS RECEIVED IND APPROVAL FOR A PHASE 1B/2 CLINICAL TRIAL OF SOQUELITINIB IN CHINA FOR THE TREATMENT OF ATOPIC DERMATITIS

Source text: ID:nGNX5kV5pT

Further company coverage: CRVS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10